1. Home
  2. TRX vs NERV Comparison

TRX vs NERV Comparison

Compare TRX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$1.13

Market Cap

253.9M

Sector

N/A

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

N/A

Current Price

$4.90

Market Cap

218.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRX
NERV
Founded
1990
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.9M
218.7M
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
TRX
NERV
Price
$1.13
$4.90
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$1.70
$10.50
AVG Volume (30 Days)
2.4M
136.6K
Earning Date
04-15-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
$84.84
N/A
Revenue Next Year
$96.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$1.93
52 Week High
$2.80
$12.46

Technical Indicators

Market Signals
Indicator
TRX
NERV
Relative Strength Index (RSI) 64.97 57.51
Support Level $1.04 $3.87
Resistance Level $1.34 $5.73
Average True Range (ATR) 0.07 0.34
MACD 0.02 0.07
Stochastic Oscillator 87.44 83.93

Price Performance

Historical Comparison
TRX
NERV

About TRX TRX Gold Corporation

TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: